

HEAD AND NECK DISEASE SITE COMMITTEE

CHELSEA HOTEL, TORONTO, ON
ROOM: WREN A&B
SUNDAY APRIL 30TH, 2022, 9:00 AM – 12:30 PM

CO-CHAIR: JOHN HILTON AND JOHN WALDRON
SENIOR INVESTIGATOR: WENDY PARULEKAR
SENIOR BIOSTATISTICIAN: WEI TU
STUDY COORDINATOR: SARAH HUNTER

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by Queen's University.

Learning Objectives

- To interpret and address, through clinical and translational research, the disease burden associated with head and neck malignancies in Canada.
- To review recent developments in the understanding of molecular biology and new therapeutics as these relate to head and neck malignancies.
- To update, review, and discuss recent results of clinical studies conducted by the Canadian Cancer Trials Group or its collaborators.
- To provide a learning environment supportive to new investigators.
- Provide an opportunity for CCTG investigators to vet new proposals and engage in collaborative multidisciplinary discussions based on feedback from peers

| | | |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|
| 9:00 am | <u>Welcome</u> | |
| 9:05 am | Single-Arm Phase II Trial of Maintenance Pembrolizumab and Eftilagimod Alpha in CPS<1% Metastatic Head and Neck Carcinoma Patients | Adi Kartolo and Brandon Meyers |
| 9:20 am | Unicancer: Trastuzumab Deruxtecan in Salivary Gland Carcinoma with HER 2+ Or 3+ Expression | John Hilton |
| 9:35 am | Head and Neck Elective Dose and Volume De-Escalation | Jillian Tsai |
| 9:50 am | Stereotactic boost and SHO rt-course Radiation Therapy for HPV-associated OroPharynx Cancer (S ₂ HORT-OPC) Trial: Phase II Randomized Trial | Houda Bahig |
| 10:05 am | <u>Adaptive Radio</u> Therapy for Locally Advanced HPV-associated <u>Oro</u> Pharynx <u>C</u> ancer (ART-OPC) | Houda Bahig |
| 10:20 am | Neoadjuvant Chemotherapy and Transoral Robotic Surgery for HPV-related Oropharyngeal Cancer: Standard versus de-escalated personalized transoral robotic surgery (NECTORS-2) | Nader Sadeghi and Nathaniel Bouganim |
| 10:35 am | Combined Targeted and Immunotherapy for Anaplastic Thyroid Cancer | Anthony Nichols |



| | | |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| 10:50 am | Combined Checkpoint Co-blockade in Resectable Oral Cavity and Larynx Cancer – a Window of Opportunity Trial | Anthony Nichols |
| 11:05 am | <u>BREAK</u> <u>Update on Approved Not Activated Trials</u> | |
| 11:20 am | HN.13 - Optimizing head and Neck Tumour And Symptom Control in Patients Unable to Tolerate Curative Intent RT: a Phase III trial Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study) | Ian Poon |
| 11:30 am | HN.12 - Promote-HN- PembROlizumab with or without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma | Anna Spreafico |
| | <u>Update on Open Trials</u> | |
| 11:40 am | HN.11- SPECT-CT Guided ELE ctive C ontralateral Neck T reatment in Lateralized Oropharynx Cancer (SELECT): For Patients with Lateralized Oropharyngeal Cancer: A Phase III Randomized Controlled Trial | John De Almeida and Ali Hosni |
| 11:50 am | HN.10- A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma | Scott Bratman |
| 12:00 pm | HN.9- Randomized Phase II Study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab versus Durvalumab plus Radiotherapy followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC) | Khalil Sultanem |
| 12:10 pm | HNC.2 (NRG-HN004) - Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin | John Waldron and Wendy Parulekar |
| 12:20 pm | <u>Endpoint Committee Updates (IND, PROs, Economics, and Correlative Biology)</u> | |
| 12:30 pm | <u>Meeting Adjourned</u> | |

